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stopping molecular-targeted therapies. The development 
of bDMARDs and targeted-molecular sDMARDs has pro-
vided a wide range of treatment options for RA. Patients 
with active RA should be treated with a treat-to-target strat-
egy after assessment of risks and benefits.
Introduction
Rheumatoid arthritis (RA) is characterized by chronic 
synovial inflammation of unknown cause. Around 1 % of 
adults are affected by RA worldwide, and the incidence 
appears to be higher in women. Failure to control active RA 
induces joint destruction, deformities in the extremities, 
deterioration of quality of life (QOL), and a high mortality 
rate [1]. The last decade has witnessed significant develop-
ments in the treatment of RA, such as disease-modifying 
antirheumatic drugs (DMARDs), including methotrexate 
(MTX), which can reduce the synovial inflammation and 
partially stop the progression of structural damage. How-
ever, although symptomatic improvement and pain relief 
have been achieved, no therapy appears to prevent disease 
progression or even disease development. The European 
League against Rheumatism (EULAR) recommends the 
use of MTX or combination therapy with a conventional 
synthetic DMARD (csDMARD) as the first-line therapy 
for RA as soon as it is diagnosed [2]. Beyond csDMARDs, 
biological DMARDs (bDMARDs) [3] and tofacitinib [4], a 
targeted sDMARD (tsDMARD), are available for the treat-
ment of RA. Biological DMARDs and tsDMRADs both 
have significant advantages and limitations in the treatment 
of RA. The aim of this paper is to summarize the benefits 
and drawbacks of these medicines for the treatment of RA 
for orthopedic surgeons.
Abstract Rheumatoid arthritis (RA) is characterized by 
chronic synovial inflammation due to unknown causes. 
Conventional synthetic disease-modifying antirheumatic 
drugs (csDMARDs), biological DMARDs (bDMARDs), 
and tofacitinib, a targeted sDMARD, can be used to treat 
RA. In clinical trials, molecular-targeted therapies showed 
a significant reduction in RA symptoms and provided pain 
relief for patients with active RA. Even if patients did not 
show clinical improvement with combination therapy 
with a bDMARD and methotrexate (MTX), some patients 
showed a significant inhibition in structural damage. The 
clinical efficacies of tofacitinib were shown to be equivalent 
to adalimumab, a bDMARD, in patients with RA treated 
with MTX. MTX is the first-line agent for the treatment of 
RA. Higher doses of MTX might be needed to maintain the 
effects of bDMARDs. Patients receiving some bDMARDs 
have been shown to have a higher risk for serious infec-
tions; thus, pre-screening for infections is important before 
beginning treatment with bDMARDs. The rates of patients 
maintaining targeted levels of disease activity after stop-
ping bDMARDs are relatively low. It is uncertain whether 
remission or low disease activity can be maintained after 
This instructional lecture was presented at the 87th Annual 
Meeting of the Japanese Orthopaedic Association, Kobe, 22 May 
2014.
 * Tatsuya Koike 
 tatsuya@med.osaka-cu.ac.jp
1 Center for Senile Degenerative Disorders (CSDD), Osaka 
City University Medical School, Abenoku, Asahimachi 
1-4-3, Osaka 545-8585, Japan
2 Search Institute for Bone and Arthritis Disease (SINBAD), 
Shirahama Foundation for Health and Welfare, Nishimurogun 
Shirahamacho 1447, Shirahama, Wakayama 649-2211, Japan
© 2015 The Japanese Orthopaedic Association. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
952 T. Koike
1 3
Molecular‑targeted medicine
Molecular-targeted therapy is one of the major modalities 
of medical treatment for cancer. For RA, csDMARDs were 
developed using an empirical approach without gaining a 
detailed understanding of their mechanism of action. How-
ever, recent developments in science have revealed more 
information about the inflammatory process that occurs in 
RA (Fig. 1), making the development of molecular-targeted 
therapy possible. Patients with RA show higher levels of 
several cytokines such as tumor necrosis factor-α (TNF-α), 
interleukin-1β (IL-1β), and IL-6. Although the precise role 
of these cytokines in the pathogenesis of RA is unknown, 
anti-TNF agents such as infliximab (IFX, monoclonal anti-
body against TNF-α) [5] or etanercept [ETN, fusion protein 
of the Fc region of a human immunoglobulin G (IgG) anti-
body linked to the extracellular portion of the human p75 
TNF-receptor, the so-called decoy receptor for TNF] [6] 
have been shown to lead to dramatic improvement in symp-
toms of RA and prevent structural damage to the joints. 
These initial successes with anti-TNF agents in the treat-
ment of RA opened avenues for new strategies with molec-
ular-targeted medicines. Currently approved molecular-tar-
geted medicines in Japan include IFX, ETN, adalimumab 
(ADA, a fully humanized monoclonal antibody against 
TNF-α by phage display platform) [7], tocilizumab (TCZ, a 
humanized anti-human IL-6 receptor antibody of the IgG1 
subclass) [8], abatacept (ABT, a T cell-blocking Fc-portion 
protein of the extracellular domain of CTLA-4) [9], goli-
mumab (GLM, a fully humanized monoclonal antibody 
against TNF-α by a transgenic mouse platform) [10], cer-
tolizumab pegol (CZP, a PEGylated Fc-free monoclonal 
antibody against TNF-α) [11], and tofacitinib (TOF, an oral 
Janus kinase inhibitor) [12]. IFX, ETN, ADA, GLM, and 
CZP are TNF-α inhibitors, and TCZ blocks the activity of 
IL-6. All of them directly target specific cytokines, whereas 
ABT decreases the level of cytokines through the inhibi-
tion of T-cell communication [13]. TOF interferes with the 
JAK-STAT intracellular signaling pathway, which mediates 
the activity of several proinflammatory cytokines. TOF is 
the only molecular-targeted therapy that can be adminis-
tered orally.
Effects of molecular‑targeted agents
In clinical trials, molecular-targeted agents have been 
shown to lead to a significant reduction in symptoms and 
provide pain relief for patients with active RA compared 
with placebo or MTX alone [6–8, 10, 12, 14–17]. Espe-
cially the combination therapy with MTX yielded superior 
clinical efficacy to monotherapy [5–8, 10–12, 14–19]. The 
efficacy of some molecular-targeted agents was similar to 
the efficacy of MTX in the monotherapy setting [14]. Fur-
thermore, these agents are expected to inhibit radiographic 
progression across all disease activity conditions, whereas 
joint damage has been shown to progress in patients with 
low and moderate disease activity levels treated with csD-
MARDs such as MTX [20]. Even in patients who did not 
show clinical improvement as evaluated by American Col-
lege of Rheumatology criteria [21], combination therapy 
with IFX and MTX provided significant inhibition of struc-
tural damage compared with inhibition in patients who 
received MTX alone [22]. There might be uncoupling of 
inflammation and joint destruction in RA. Here, the author 
provided roentgenograms of a case. A 52-year-old female 
suffering from active rheumatoid arthritis had been treated 
with IFX and MTX since October 2008. Although she 
did not show an adequate response to IFX therapy with-
out improvement of DAS, dramatic repair of the proximal 
interphalangeal (PIP) joint of her right middle finger was 
observed in May 2009 (Fig. 2a, b).
Clinical efficacy has also been seen with the available 
bDMARDs compared with placebo. Currently, there is 
only one head-to-head comparison report on the effects 
of bDMARDs [9]. In the AMPLE trial [9], subcutaneous 
ABT and ADA did not show any significant differences in 
clinical, functional, and radiographic outcomes or adverse 
events. However, it should be noted that this trial was a 
randomized controlled trial (RCT) but not conducted in a 
double-blind fashion. Recently, the clinical efficacies of 
DMARDs have been estimated based on the improvement 
of the Disease Activity Score 28 (DAS28) [23]. The DAS28 
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Fig. 1  Critical points blocked by molecular-targeted agents and 
others in the inflammatory cascade. Each agent blocks the critical 
points indicated by rods. IFX infliximab, ADA adalimumab, TCZ 
tocilizumab, ABT abatacept, GLM golimumab, CZP certolizumab 
pegol, TOF tofacitinib, MTX methotrexate, LEF leflunomide, IL-1β 
interleukin-1β, TNF-α tumor necrosis factor-α, IL-6 interleukin-6
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consists of four components: tender joint count, swollen 
joint count, visual analog scale (VAS) score of the patient’s 
global health and laboratory parameters including the 
erythrocyte sedimentation rate (ESR) or C-reactive protein 
(CRP). Except for laboratory parameters, the other compo-
nents are subjective, and the author thinks that caution is 
required when interpreting the results of a clinical trial that 
was not performed in a double-blind setting. However, it is 
a very important result that the joint destruction suppres-
sant effect was the same between those two bDMARDs [9].
All bDMARDs are administered intravenously or subcu-
taneously mainly because of the difficulty of oral adminis-
tration by protein preparation. On the other hand, a recently 
approved small molecule, TOF, is taken orally and might 
be convenient for patients [4]. TOF was shown to be sig-
nificantly more effective than placebo, and the clinical 
efficacies of TOF were equivalent to ADA in patients with 
RA treated with MTX [12]. Although TOF could provide 
an effective treatment option for patients with inadequate 
response to TNF-α inhibitors, such as IFX, ADA, and ETN 
[18], its safety profile, including the incidence of malig-
nancy and infection by herpes zoster, requires long-term 
observation, as TOF blocks signaling of multiple cytokine 
intracellularly.
The importance of MTX
MTX is the anchor drug for the treatment of RA. MTX 
is recommended for use as the first DMARD for the 
treatment of RA in patients who can tolerate it [2]. With 
MTX monotherapy, higher and rapidly escalated doses of 
MTX are effective and well tolerated, especially in West-
ern populations [24]. Combination therapy with MTX 
and TNF-α inhibitors has been shown to be effective 
compared with MTX monotherapy [25–29]. However, 
the minimally effective dose of MTX used in combina-
tion with bDMARDs has not been determined. Recently, 
Burmester and colleagues reported the results of an RCT 
studying the minimal effective dose of MTX for com-
bination therapy with ADA [30]. The authors randomly 
divided MTX- and bDMARDs-naïve early RA patients 
with DAS28-CRP ≥3.2, CRP ≥1.5 mg/dl, ≥1 bony ero-
sion, and seropositivity into four groups receiving 2.5, 5, 
Fig. 2  A case showing radiological repair despite inadequate 
response to a tumor necrosis factor-α inhibitor. A 52-year-old female 
suffering from active rheumatoid arthritis had been treated with IFX 
and MTX since October 2008. Although she did not show an ade-
quate response to IFX therapy without improvement of disease activ-
ity, dramatic repair of the proximal interphalangeal (PIP) joint of her 
right middle finger was observed in May 2009. Roentgenogram of 
the PIP joints of the right middle finger in October 2008 (a) and May 
2009 (b). IFX infliximab, MTX methotrexate
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Fig. 3  Schematic protocol of the CONCERTO study. Patients with 
inclusion criteria for this trial had a disease duration under 1 year, 
DAS28-CRP ≥3.2, swollen joint count ≥6 of 66 joints assessed, ten-
der joint count ≥8 of 68 joints assessed, CRP ≥1.5 mg/dl or eryth-
rocyte sedimentation rate ≥28 mm/h, and ≥1 bony erosion, RF, or 
anti-CCP antibody positivity. Patients in the 20 mg/week MTX treat-
ment group were started at 10 mg/week, which was escalated by 
2.5 mg every 2 weeks to 20 mg/week by 8 weeks. In case of MTX 
intolerance/toxicity, blinded MTX dose reduction by 5 mg/week was 
performed. MTX methotrexate, DAS28 disease activity score 28, CRP 
C-reactive protein, RF rheumatoid factor, ACPA anti-citrullinated pro-
tein antibody, LDA low disease activity, mTSS modified total Sharp 
score, HAQ health assessment questionnaire. The author created the 
figure from the contents of Ref. 30
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Fig. 4  The effects of increasing doses of MTX on ADA therapy for 
RA. DAS28 disease activity score 28, CRP C-reactive protein, SDAI 
simplified disease activity index, mTSS modified total Sharp score, 
HAQ health assessment questionnaire. The author created the figure 
from the contents of Ref. 30
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10, or 25 mg MTX once weekly in a double-blinded man-
ner (Fig. 3). All patients had received ADA 40 mg every 
2 weeks in an open-label manner. Statistically significant 
increases in the percentage of patients achieving DAS-low 
disease activity (LDA; DAS28-CRP <3.2), DAS remission 
(DAS28-CRP <2.6), and simplified disease activity index 
remission (SDAI; ≤3.3) were seen with escalating doses 
of MTX in combination with ADA at 26 weeks (Fig. 4). 
Similar effects of increasing doses of MTX on the lack of 
progression rate of small joint destruction [modified total 
Sharp score (∆mTSS) <0.5] and minimal clinically impor-
tant differences in function [Health Assessment Question-
naire (HAQ) change ≤0.22 from baseline] were observed, 
although differences between groups were not significant 
(Fig. 4). However, there was no significant differences 
between 10 and 20 mg/week MTX doses on accelerating 
the efficacy of ADA. Compared with Western people, Asian 
subjects have lower body weight. Thus, in cases using com-
bination therapy with bDMARDs and MTX, MTX 20 mg a 
week might be a higher dose than needed. More RCTs are 
required to determine the minimal effective dose of MTX 
for combination therapy with bDMARDs worldwide.
Adverse events associated with molecular‑targeted 
therapies
Pneumonia, tuberculosis, Pneumocystis jirovecii pneumo-
nia, interstitial pneumonitis, and viral infections such as 
hepatitis B, C, and herpes zoster (HZ) are severe adverse 
events observed during treatment with molecular-tar-
geted agents. Patients on TNF-α inhibitors have a higher 
risk of such serious infections compared with patients on 
sDMARDs. There was no increased risk for malignan-
cies in patients with bDMARDs therapy [31]. In terms of 
adverse events with tsDMARD, increased HZ rates were 
observed among patients treated with TOF, especially in 
an Asian population [32]. The best way to prevent infec-
tions during treatment with bDMARDs or tsDMARD is 
to screen patients for risk factors before starting therapy. 
Physicians should survey the past history of infections such 
as tuberculosis, hepatitis B and C by the interview, radio-
graphic examination including computed tomography and 
laboratory tests including interferon-gamma release assay 
(IGRA) for Mycobacterium tuberculosis infection, hepati-
tis B surface antigen (HBsAg), hepatitis B surface antibody 
(HBsAb), hepatitis B core antibody (HBcAb), and hepatitis 
C virus antibody (HCVAb). Two IGRAs are commercially 
available at the present time. They are the QuantiFERON® 
TB Gold In-Tube test (QFT-GIT) and SPOT®TB test 
(T-Spot). Furthermore, patients with RA are at increased 
risk of developing comorbid conditions and serious infec-
tions [33]; careful examination should be performed to 
detect abnormalities in cardiac function, renal function, 
liver function, the number of lymphocytes and white blood-
cell count. Some of the important causes of serious adverse 
events during the treatments with bDMARDs or tsDMARD 
are preventable with such careful screenings and consulta-
tion with a pulmonologist or hepatologist if necessary [34]. 
Use of the HZ vaccination at the start of treatment with 
bDMARDs or tsDMARD is not recommended because the 
HZ vaccine is an active one.
Treat‑to‑target strategy (Fig. 5)
A treat-to-target (T2T) strategy [35] has been adopted in 
general practice in medicine. For example, the goal of treat-
ment in diabetes mellitus (DM) or hypertension (HT) is the 
prevention of cardiovascular events. To reach the treatment 
goal in DM and HT, physicians start treatments after setting 
targets for HbA1c or blood pressure, respectively. Before 
the development of bDMARDs or tsDMARD, the use of a 
T2T strategy in the field of RA has been unrealistic. Cur-
rently, a T2T strategy is an effective approach using a com-
bination of csDMARDs instead of bDMARDs, and use of 
bDMARDs is not essential for a T2T strategy [36]. In my 
opinion, the goal of RA treatment is to prevent a decline 
in QOL, and the current target to achieve this might be the 
DAS28 score. We are living in an era when it is easy to 
practice a T2T strategy by using bDMARDs or tsDMARD.
Limitations of molecular‑targeted agents
RA is a heterogeneous chronic disease, and no therapeutic 
agent has been identified that is universally and persistently 
effective in all patients. This is also the case in bDMARDs 
or tsDMARD. It is difficult to predict clinical outcomes 
in RA in its natural course and during treatment with 
Target
DM HT RA
Prevention
of CVD
Keeping 
QOL
HbA1c BP DAS
Goal
Fig. 5  Concept of treat-to-target strategy for diabetes mellitus (DM), 
hypertension (HT), and rheumatoid arthritis (RA). BP blood pressure, 
DAS disease activity score, CVD cardiovascular disease
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bDMARDs or tsDMARD [37]. The use of molecular-tar-
geted agents is associated with the adverse events reviewed 
above, as well as concerns regarding costs. After achiev-
ing good response with treatment with molecular-targeted 
medicines, it is uncertain that patients can maintain remis-
sion or low disease activity after stopping these drugs. The 
rates of patients maintaining targeted disease activity level 
after stopping bDMARDs in clinical trials driven by a T2T 
strategy were relatively low [38–40], and previous studies 
for the discontinuation of bDMARDs had several methodo-
logical limitations [41].
Conclusion
The development of bDMARDs and tsDMARD provided 
a wide range of treatment options for RA. We should con-
sider the use of these agents using a T2T strategy after 
assessing the risks, benefits, and costs, as well as the impact 
of these agents on QOL. Long-term studies to confirm the 
results from short RCTs are required.
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